维生素E | 30999-06-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 维生素E
• 中文别名: 维生素E(标准品)；维生素E(油状)；维生素E(59-02-9)
• 英文名称: Tocophersolan
• 英文别名: 1-O-(2-hydroxyethyl) 4-O-[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] butanedioate
• CAS: 30999-06-5
• 化学式: C₃₅H₅₈O₆
• 分子量: 574.8
• InChiKey: AOBORMOPSGHCAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.9
• 重原子数：
  41
• 可旋转键数：
  20
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  82.1
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2936280000

反应信息

• 作为反应物：
  描述：

  cyclosporin A 、 维生素E 在 水 、 Cyclosporine TPGS 作用下， 以 乙醇 为溶剂， 反应 16.17h， 生成 Cyclosporine TPGS
  参考文献：
  名称：

  Drug delivery systems utilizing liquid crystal structures

  摘要：

  本发明提供了维生素E TPGS/药物组合物和方法，其无需表面活性剂或非挥发性共溶剂，因为活性药物成分直接溶解在维生素E TPGS中形成真正的分子溶液--而不是乳液或微乳液。本发明提供了一种缓慢溶解的TPGS/药物基质，该基质吸收胃肠道液体进入剂型/液体界面，形成一种凝胶状液晶。这个凝胶前沿形成了一个液晶边界，药物溶解度最高。在这个液晶/胃肠液体边界处，发生同步，液晶的形成速率等于水界面上液晶的溶解速率，从而在胃肠道中控制有序释放药物。溶解速率也受剂型几何形状的控制。本发明的固态维生素E TPGS/药物基质可以固化并压缩成片剂或填充到胶囊中，与其他赋形剂、粘合剂和/或填充剂一起使用。本发明的固态TPGS/药物溶液也可以通过加水制成立即释放的液体制剂，或通过使用不透水或半透水的障壁或涂层包围片剂的部分来制成控制释放系统的固态片剂。

  公开号：

  US05891845A1
• 作为试剂：
  描述：

  维生素E 、 咖啡因 在 咖啡因 、 维生素E 作用下， 以The emulsion of experiment 17 gives similar的产率得到Caffeine TPGS
  参考文献：
  名称：

  Solubilization of Pterostilbene and Resveratrol in Aqueous Beverages

  摘要：

  在一种实施例中，本申请披露了在水性介质中溶解紫檀素或白藜芦醇或其混合物的组合物和方法。

  公开号：

  US20160052850A1

文献信息

• Pharmaceutical Composition Comprising Temozolomide Ester
  申请人：Wang Yongfeng

  公开号：US20080044457A1

  公开（公告）日：2008-02-21

  The present invention discloses general formula I of Temozolomide-8-carboxylate compounds, the process for preparation, pharmaceutical compositions comprising the compounds and the use of the compounds and pharmaceutical compositions for the manufacture of an antitumor medicament. The said pharmaceutical composition comprises one or more general formula I Temozolomide-8-carboxylate compounds as active ingredient, together with conventional pharmaceutical carriers. The composition also comprises one or more pharmaceutically acceptable acidic material, optionally second or tertiary alcohol or ester or ether derivatives thereof. The said pharmaceutical composition can be made into various common formulations, particularly oral formulations as well as topically transdermal patches. The present invention also discloses the application of the compounds and the compositions to treat tumor.

  本发明公开了特莫唑酰胺-8-羧酸酯化合物的通用式I，其制备过程，包含该化合物的制药组合物以及用于制造抗肿瘤药物的化合物和制药组合物的用途。所述制药组合物包括一种或多种通用式I特莫唑酰胺-8-羧酸酯化合物作为活性成分，以及常规的制药载体。该组合物还包括一种或多种药学上可接受的酸性物质，可选的第二或第三醇或酯或醚衍生物。该制药组合物可以制成各种常见的配方，特别是口服制剂以及局部透皮贴片。本发明还公开了该化合物和组合物用于治疗肿瘤的应用。
• PROCESS FOR RELEASE OF BIOLOGICALLY ACTIVE SPECIES
  申请人：AUGUSTIJNS Patrick

  公开号：US20090318519A2

  公开（公告）日：2009-12-24

  A process for the release of a biologically active species comprising the steps of: providing a mesoporous oxide-based material having structural order and at least one level of porosity; fixing or immobilizing said biologically active species in said ordered mesoporous oxide; and providing said ordered mesoporous oxide with said fixed or immobilized biologically active species in vivo thereby realizing intraluminally induced substantially pH-independent supersaturation of said biologically active species resulting in enhanced transepithelial transport; wherein said biologically active species is a poorly soluble therapeutic drug classified as belonging to Class II or Class IV of the Biopharmaceutical Classification System and said ordered mesoporous oxide has a pore size in the range of 4 to 14 nm.

  一种释放生物活性物种的方法，包括以下步骤：提供具有结构有序性和至少一级多孔性的介孔氧化物基材料；将所述生物活性物种固定或固定化在所述有序介孔氧化物中；并在体内提供具有所述固定或固定化生物活性物种的有序介孔氧化物，从而实现基腔内诱导的基本上pH无关的生物活性物种过饱和度，导致增强的经上皮转运；其中，所述生物活性物种是属于生物制药分类系统的II类或IV类的难溶性治疗药物，所述有序介孔氧化物的孔径在4到14纳米范围内。
• Pharmaceutical composition comprising temozolomide ester
  申请人：Tian Jin Tasly Group Co., Ltd.

  公开号：US07579336B2

  公开（公告）日：2009-08-25

  The present invention discloses general formula I of Temozolomide-8-carboxylate compounds, the process for preparation, pharmaceutical compositions comprising the compounds and the use of the compounds and pharmaceutical compositions for the manufacture of an antitumor medicament. The said pharmaceutical composition comprises one or more general formula I Temozolomide-8-carboxylate compounds as active ingredient, together with conventional pharmaceutical carriers. The composition also comprises one or more pharmaceutically acceptable acidic material, optionally second or tertiary alcohol or ester or ether derivatives thereof. The said pharmaceutical composition can be made into various common formulations, particularly oral formulations as well as topically transdermal patches. The present invention also discloses the application of the compounds and the compositions to treat tumor.

  本发明公开了Temozolomide-8-羧酸酯化合物的通式I，其制备方法，包含该化合物的制药组合物以及用于制造抗肿瘤药物的化合物和制药组合物的用途。所述制药组合物包括一种或多种通式I Temozolomide-8-羧酸酯化合物作为活性成分，以及常规制药载体。该组合物还包括一种或多种药学上可接受的酸性物质，可选择第二或第三醇或酯或醚衍生物。所述制药组合物可以制成各种常见的制剂，特别是口服制剂以及局部透皮贴剂。本发明还公开了应用该化合物和组合物治疗肿瘤的方法。
• THERAPEUTIC EYE DROP COMPRISING DOXYCYCLINE AND A STABILIZER
  申请人：GILBARD JEFFREY P.

  公开号：US20120190653A1

  公开（公告）日：2012-07-26

  The present invention provides stable aqueous doxycycline aqueous solutions suitable for pharmaceutical, especially ophthalmic, use. The doxycycline aqueous solutions have a pH ranging from 4.5-8, and contain an antioxidant and a stabilizer such as caffeine, creatine or mixtures thereof. The solutions have improved lifetimes and can be used topically.

  本发明提供了稳定的水溶性强力霉素水溶液，适用于制药，特别是眼科用途。强力霉素水溶液的pH值在4.5-8之间，并含有抗氧化剂和稳定剂，如咖啡因，肌酸或其混合物。这些溶液具有改善的寿命，并可用于局部应用。
• Process for release of biologically active species from mesoporous oxide systems
  申请人：Katholieke Universiteit Leuven

  公开号：US08258137B2

  公开（公告）日：2012-09-04

  A process for the release of a biologically active species comprising the steps of: providing a mesoporous oxide-based material having structural order and at least one level of porosity; fixing or immobilizing said biologically active species in said ordered mesoporous oxide; and providing said ordered mesoporous oxide with said fixed or immobilized biologically active species in vivo thereby realizing intraluminally induced substantially pH-independent supersaturation of said biologically active species resulting in enhanced transepithelial transport; wherein said biologically active species is a poorly soluble therapeutic drug classified as belonging to Class II or Class IV of the Biopharmaceutical Classification System and said ordered mesoporous oxide has a pore size in the range of 4 to 14 nm.

  一种释放生物活性物质的方法，包括以下步骤：提供具有结构有序性和至少一级孔隙度的介孔氧化物基材料；将所述生物活性物质固定或固定在所述有序介孔氧化物中；并在体内提供具有所述固定或固定生物活性物质的有序介孔氧化物，从而实现基腔内诱导的基本pH无关的生物活性物质过饱和度，从而增强横上皮转运。其中，所述生物活性物质是属于生物制药分类系统的II类或IV类的溶解度差的治疗药物，而所述有序介孔氧化物的孔径范围为4至14纳米。